

Vita Life Sciences Limited

ACN 003 190 421

ABN 35 003 190 421

Corporate Office

1/102 Bath Road,
Kirrawee NSW 2232

P.O. Box 3143

Kirrawee NSW 2232

T/Free: 1800 852 222

T: 02 9545 2633

F: 02 9545 1311

vitalifesciences.com

28th Nov 2022

Market Announcements
Australian Securities Exchange Ltd
20 Bridge Street
Sydney, NSW 2000

FY2022 TRADING GUIDANCE

Vita Life Sciences (**ASX: VLS**) announces the following guidance for the Full Year ending 31 Dec 2022 (FY 2022):

Sales: \$64.0m-\$65.0m (FY2021: \$57.1m, FY2020: \$46.5m)

Pre-tax Profit: \$9.5-10.0m (FY2021: \$11.2m, FY2020: \$8.1m)

FY2022 Revenue:

- Moderate growth across the key markets of Australia, Malaysia, Singapore and export sales into China is expected; and
- New customer acquisition and increased market penetration continues to support the Group's sales performance.

FY2022 Pre-tax Profit:

- Reflects the Company's brand building investment strategy to drive higher consumer sales and increase retailer trade support; and
- Normalised advertising and promotional expenditure; i.e. FY2020-FY2021 expenditure was reduced due to Covid-19 uncertainties.

VLS remains well positioned to execute its existing strategy to drive long term sustainable growth. Market conditions across complementary medicine categories continue to remain strong, albeit softer trading conditions are expected in 1H2023.

This announcement has been authorised by the Board of Directors.



Andrew O'Keefe
Managing Director

Email: enquiries@vitalifesciences.com.au